Platinum analogues

Daiichi Sankyo Co., Ltd. · Phase 2 active Small molecule

Platinum analogues is a Small molecule drug developed by Daiichi Sankyo Co., Ltd.. It is currently in Phase 2 development. Also known as: Cisplatin, Carboplatin, Nedaplatin.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

• Baseline phase 2 → approval rate +15.3pp
  Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Platinum analogues
Also known as	Cisplatin, Carboplatin, Nedaplatin
Sponsor	Daiichi Sankyo Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors
• Cisplatin, Carboplatin, and Oxaliplatin Interactions With Plasma Proteins
• Oxaliplatin to Treat Advanced Cancers With Liver Dysfunction (PHASE1)
• Oxaliplatin in Cancer Patients With Impaired Kidney Function (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Platinum analogues CI brief — competitive landscape report
• Platinum analogues updates RSS · CI watch RSS
• Daiichi Sankyo Co., Ltd. portfolio CI

Frequently asked questions about Platinum analogues

What is Platinum analogues?

Platinum analogues is a Small molecule drug developed by Daiichi Sankyo Co., Ltd..

Who makes Platinum analogues?

Platinum analogues is developed by Daiichi Sankyo Co., Ltd. (see full Daiichi Sankyo Co., Ltd. pipeline at /company/daiichi-sankyo-co-ltd).

Is Platinum analogues also known as anything else?

Platinum analogues is also known as Cisplatin, Carboplatin, Nedaplatin.

What development phase is Platinum analogues in?

Platinum analogues is in Phase 2.

Related

• Manufacturer: Daiichi Sankyo Co., Ltd. — full pipeline
• Also known as: Cisplatin, Carboplatin, Nedaplatin